Gender-Based Differences in Outcomes After Percutaneous Coronary Intervention of Chronic Total Occlusions (Insights from a Large Single-Center Registry).

Patients who undergo percutaneous coronary intervention (PCI) of chronic total occlusions (CTO) are at a high risk for both periprocedural and post-procedural adverse events. Whether gender-differences in outcomes exist after PCI of CTO remain unclear. Therefore, we sought to investigate gender-based differences in outcomes after CTO-PCI. All patients who underwent elective CTO intervention from January 2012 to December 2017 at The Mount Sinai Hospital (New York, New York) were included. The primary end point of interest was major adverse cardiac events defined as the composite of death, myocardial infarction, and target vessel revascularization at 1 year of follow-up. A total 1,897 patients were included, of which 368 were women (19.4%). Mean follow-up time was 174 days. Women were older (66.8 ± 11.3 years vs 62.6 ± 10.9 years) and had a higher prevalence of co-morbidities including diabetes and chronic kidney disease. There were no significant differences in the rate of successful CTO-PCI between groups (73.5% vs 73.2%, p = 0.91). Women had higher rates of procedure-related complications including increased risk of post-procedural bleeding (4.1% vs 1.8%, p = 0.009) and acute vessel closure (1.36% vs 0.2%, p = 0.009). In multivariable-adjusted analysis, female gender was associated with higher risk of major adverse cardiac event and target vessel revascularization at 1 year. In conclusion, in this large single-center study, women who underwent percutaneous CTO revascularization experienced higher rates of periprocedural complications and worse clinical outcomes at 1 year compared with men. Further research is needed to address disparities in gender-specific outcomes of CTO-PCI.
Competing Interests: Declaration of Competing Interest Dr. Kini reports as industry-sponsored lectures: miscellaneous teaching and lectures at academic institutions. Roxana Mehran: consulting: Dr. Kieffer reports as Equity: Elixir Medical Corporation, STEL, ControlRad; industry-sponsored lectures: Asan University South Korea, Brazilian Cardiology Society, COLOMBIA webinar, China Cardiology Conference, Europa Group, Gaffney Events, India Webinar, India Webinar Mumbai, Samin Sharma Foundation, Society for Cardiovascular Angiography and Interventions, St. Francis Hospital, Taiwan Cardiology Conference, Tarsus, University of Florence, University of Purchase, WebMD, webinar APSCJCS; Scientific Advisory Board: American College of Cardiology. Dr. Sharma reports as equity: Eternal Heart Care Centre and Research Institute Private Limited; Industry Sponsored Lectures: Abbott Laboratories, Boston Scientific Corporation, Cardiovascular Systems, Inc., miscellaneous teaching and lectures at academic institutions. The remaining authors have no competing interests to declare.
(Copyright © 2023 Elsevier Inc. All rights reserved.)